RT Plus EGFR-TKI for Wild-type NSCLC

NCT02738983 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

Interventions

DRUG: Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)
RADIATION: Radiotherapy

Sponsor

Hangzhou Cancer Hospital